SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : Lincoln Pharmaceuticals Ltd

BSE: 531633 NSE: LINCOLN ISIN: INE405C01035
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does Lincoln Pharmaceuticals Ltd belong to?
Lincoln Pharmaceuticals Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is Lincoln Pharmaceuticals Ltd a good quality company?
Lincoln Pharmaceuticals Ltd is a good quality company, based on a consistently good 10 year financial track record.
Q.3 Is Lincoln Pharmaceuticals Ltd undervalued or overvalued?
Lincoln Pharmaceuticals Ltd appears Somewhat overvalued, as its key valuation ratios are above with their past averages.
Q.4 Is Lincoln Pharmaceuticals Ltd a good buy now?
Lincoln Pharmaceuticals Ltd is a neutral opportunity now, based on stable price trend analysis suggesting prices may move sideways. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd revenue growth is 7.4% for FY-2025 , which is below its 5 year CAGR of 10.6% , indicating slower growth.
Q.2 Gross Profit margin of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd Gross profit margin which is the profit after deduction of direct costs, is 18.7% for FY-2025 , which is below its 5 year median of 20.9% , indicating decreasing margins.
Q.3 Operating Profit Margin of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is 16.31% for FY-2025 , which is below its 5 year median of 17.5% indicating decreasing margins.
Q.4 Net Profit Margin of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd Net Profit Margin is 13.21% for FY-2025 , is below with its 5 year median of 14.69%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin 18.7 20.9
Operating Profit Margin 16.31 17.5
Net Profit Margin 13.21 14.69
Q.5 Return on Asset of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd Return on Asset is 10.65%, which is below its 5 year historical median of 12.77%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd Return on equity is 13.02% for FY-2025 , which is below its historical median of 17.04%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd Return on capital employed is 17.55% for FY-2025 , which is above its estimated weighted average cost of capital(WACC) 14%, indicating value creation.
Q.8 Cash conversion cycle of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd Cash conversion cycle is 76 days, above its historical median of 76 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.84 0.89
ROE 13.02 17.04
ROCE 17.55 22.53
Cash Conversion Cycle 76 days 76 days
Q.9 Debt to Equity ratio of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd Debt-to-Equity ratio is 0.00 , which is lower with the industry average of 0.15 , indicating lower debt levels in the industry.
Q.10 Debt to cash flow from operations of Lincoln Pharmaceuticals Ltd?
Lincoln Pharmaceuticals Ltd Debt to cash flow from operations is 0 , which is at a healthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of Lincoln Pharmaceuticals Ltd?
Promoters hold 49.78% of the Lincoln Pharmaceuticals Ltd, with 0.00% of their stake pledged, indicating no pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of Lincoln Pharmaceuticals Ltd vs industry peers?
Lincoln Pharmaceuticals Ltd revenue CAGR is 10.63% , compared to the industry median CAGR of 5.54% , indicating faster growth and gaining its market share.
Profit Metrics
Current Level Industry Median
Revenue 623.2 137.1
Gross Profit 116.5 15.1
Operating Profit 101 16
Net Profit 82 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.84 0.8
ROE 13.02 8.91
ROCE 17.55 11.59
Cash Conversion Cycle (days) 75.78 76

Valuation & price assessment

Q.1 Stock return of Lincoln Pharmaceuticals Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 14.1% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price 14.1% 19.8% 13% 3.8%
Q.3 Valuation ratios of Lincoln Pharmaceuticals Ltd vs historical?
The current P/E is higher that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings 13.51 9.32 40.28
Price to Book 1.59 1.53 2.77
Price to Sales 1.82 1.28 2.65
EV to EBITDA 8.93 6.44 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×